Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022

undefined; undefined; Kevin O’Laughlin; Farrell A. Tobolowsky; Riad Elmor; Rahsaan Overton; Siobhán M. O’Connor; Inger K. Damon; Brett W. Petersen; Agam K. Rao; Kevin Chatham-Stephens; Patricia Yu; Yon Yu; Sarah Ahmadi; Rachel Avery; Kathryn Bean; Leah Beavers; Kim Belanger Giguere; Joi Brownlee; Catherine Campbell; Maggie Cheng; Rachel Clinton; Taylor Coleman; Monique S. Davis; Marie Dubreus; Meryl Henry; Sujeith B. Lozoya; Jahnae Morgan; Kalimah Muhammad; Corinne M. Parker; Nigel Peters; Ellery Rybak; Andrew Schwenk; Jessica van Loben Sels; Max Veillard,

Journal ArticleOPEN ACCESS

Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022

O’Laughlin K
et al.

MMWR. Morbidity and Mortality Weekly Report (2022) 71(37) 1190-1195

DOI: 10.15585/mmwr.mm7137e1

103Citations

86Readers

Abstract

On September 9, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr).

Cite

CITATION STYLE

APA

O’Laughlin, K., Tobolowsky, F. A., Elmor, R., Overton, R., … Veillard, M. (2022). Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022. MMWR. Morbidity and Mortality Weekly Report, 71(37), 1190–1195. https://doi.org/10.15585/mmwr.mm7137e1

Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022

Abstract

Cite

Register to see more suggestions